JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its second quarter 2013 investor conference webinar scheduled on September 10, 2013 at 16:00 (EET).
Webinar will be hosted by the member of the management board Salvis Lapiņš. The presentation will be in English.
During the webinar topics in relation to JSC Olainfarm latest activities and analysis of second quarter 2013 financial results will be discussed.
After the presentation investors will be welcomed to ask questions. Due to the limited webinar time, please send in your questions in advance till September 9 to e-mail: firstname.lastname@example.org.
What is webinar?
Webinar is a virtual conference, during which company’s representative gives information about the company and its future plans. Webinar allows interactive communication and a possibility to ask questions and get answers directly from the company.
How to join the webinar?
To join the webinar, please go to the site http://ej.uz/OLF092013 on September 10, 2013 at 16:00, choose „Enter as a guest”, type in your name, surname and click „enter”. You will be then directed to the webinar screen. Prior registration is not necessary.
Additional information on the webinar
All you need to have is a computer with internet connection and headphones. No additional installations of special programs are necessary.
You will be able to ask questions in writing or just listen to the host of webinar.
Join the webinar and be the first one to hear the news!
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Information prepared by:
Member of the Board
Tel: +371 6 7013 717
Cell: +371 2 6448 873